Fully Individualized Trial Endpoints (FIEPs)
Fully Individualized Clinical Trial Endpoints (FIEPS) represent individualized, longitudinal, and patient-specific endpoints rather than population averages.
Our models estimate:
Sample size reduction: 30–40%
Trial duration reduction: 35–50%
Cost reduction: 45–55%
We argue that FIEPs represent a break-through innovation in clinical research. To reach regulatory maturity, they require Human–AI hybrid intelligence to reach regulatory maturity.
Please see the Whitepaper & Download section of this webpage to download our Industrial Whitepaper on FIEPS, which includes the background, concept, examples, model calculations, and a pathway for regulatory acceptance of the FIEPS innovation.
With FIEPS we shift the focus from population averages to patient-specific outcome architectures. We develop methodological frameworks that allow dynamic endpoint modeling based on individual disease trajectories, biomarker constellations, and real-world functional parameters.
By embedding longitudinal real-world data, digital biomarkers, and continuous monitoring streams into trial designs, we aim to transform clinical studies into learning systems rather than isolated experiments. This enables more granular signal detection, earlier therapeutic differentiation, and a more precise understanding of treatment response heterogeneity. At the same time, we work on statistical and governance models that ensure interpretability, robustness, and regulatory credibility of individualized analyses.
Our goal is not only to increase efficiency, but to redefine evidentiary standards for precision medicine in a data-rich research environment.
Ultimately, we see clinical research evolving into an adaptive ecosystem where AI-supported modeling, transparent governance, and individualized evidence generation converge to support next-generation precision therapeutics.